Author

Hemantkumar Deokar

Rosalind Franklin University - Cited by 517 - Medicinal Chemistry - QSAR - Molecular Modeling - Computational Chemistry - Drug Design

Biography

Dr. Hemant kumar Deokar  is currently working at Pharmaceutical Department. Hemant is research interests includes Pharmaceutical in Homology modeling. Hemant serving as an editorial member and reviewer of several international reputed journals. Hemant has successfully completed his Administrative responsibilities. Hemant has authored of many research articles/books related to Medicine.
Title
Cited by
Year
Novel quinoline and naphthalene derivatives as potent antimycobacterial agents
RS Upadhayaya, JK Vandavasi, RA Kardile, SV Lahore, SS Dixit, ...European journal of medicinal chemistry 45 (5), 1854-1867, 2010201
139
2010
3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues
DC Juvale, VV Kulkarni, HS Deokar, NK Wagh, SB Padhye, VM KulkarniOrganic & Biomolecular Chemistry 4 (15), 2858-2868, 2006200
66
2006
Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl) pyrimidines as COX-2 inhibitors
UA Shah, HS Deokar, SS Kadam, VM KulkarniMolecular diversity 14, 559-568, 2010201
64
2010
Synthesis and structure–activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel
N Rodrigues, K Bennis, D Vivier, V Pereira, FC Chatelain, E Chapuy, ...European journal of medicinal chemistry 75, 391-402, 2014201
37
2014
Inhibition of gastric tumor growth by a novel Hsp90 inhibitor
C Lu, D Liu, J Jin, H Deokar, Y Zhang, JK Buolamwini, X Yu, C Yan, ...Biochemical pharmacology 85 (9), 1246-1256, 2013201
32
2013
3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation
NK Wagh, HS Deokar, DC Juvale, SS Kadam, VM KulkarniNISCAIR-CSIR, India, 2006200
26
2006
Inhibiting β-catenin by β-carboline-type MDM2 inhibitor for pancreatic cancer therapy
JJ Qin, W Wang, X Li, H Deokar, JK Buolamwini, R ZhangFrontiers in pharmacology 9, 5, 2018201
21
2018
Synthesis, biological evaluation and modeling studies of new pyrido [3, 4-b] indole derivatives as broad-spectrum potent anticancer agents
SA Patil, JK Addo, H Deokar, S Sun, J Wang, W Li, DP Suttle, W Wang, ...Drug designing: open access 6 (1), 202
17
2017
Identification of PDZ ligands by docking-based virtual screening for the development of novel analgesic agents
N Bouzidi, H Deokar, A Vogrig, B Boucherle, I Ripoche, ...Bioorganic & medicinal chemistry letters 23 (9), 2624-2627, 2013201
12
2013
QSAR analysis of N-myristoyltransferase inhibitors: antifungal activity of benzofurans
HS Deokar, P Puranik, VM KulkarniMedicinal chemistry research 18, 206-220, 2009200
12
2009
Synthesis and evaluation of bidentate ligands designed to interact with PDZ domains
B Boucherle, A Vogrig, H Deokar, N Bouzidi, I Ripoche, I Thomas, P Marin, ...Bioorganic & medicinal chemistry 19 (14), 4346-4354, 202
11
2011
QSAR studies of new pyrido[3,4-b]indole derivatives as inhibitors of colon and pancreatic cancer cell proliferation
H Deokar, M Deokar, W Wang, R Zhang, JK BuolamwiniMedicinal Chemistry Research 27, 2466-2481, 2018201
10
2018
Targeted brain tumor therapy by inhibiting the MDM2 oncogene: in vitro and in vivo antitumor activity and mechanism of action
SR Punganuru, V Arutla, W Zhao, M Rajaei, H Deokar, R Zhang, ...Cells 9 (7), 1592, 2020202
10
2020
NMR evaluation of interactions between substituted-indole and PDZ1 domain of PSD-95
A Vogrig, B Boucherle, H Deokar, I Thomas, I Ripoche, LY Lian, S DuckiBioorganic & medicinal chemistry letters 21 (11), 3349-3353, 2011201
8
2011
A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido [b] indole anticancer agent, and its application to a mouse PK study
S Nag, JJ Qin, S Patil, H Deokar, JK Buolamwini, W Wang, R ZhangJournal of Chromatography B 969, 235-240, 2014201
7
2014
SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo
Y Wang, C Yang, MM Sims, JR Sacher, M Raje, H Deokar, P Yue, ...Cancer Letters 533, 21514, 2022202
6
2022
Design, synthesis, pharmacological screening and molecular docking of biphenyl analogues as antiinflammatory agents (Part-I)
UA Shah, NK Wagh, HS Deokar, SS Kadam, VM KulkarniJournal of Pharma and Bio Sciences 1 (4), 501, 2010201
6
2010
Targeting MDM2 for neuroblastoma therapy: in vitro and in vivo anticancer activity and mechanism of action
W Wang, X Wang, M Rajaei, JY Youn, A Zafar, H Deokar, JK Buolamwini, ...Cancers 12 (12), 361, 2020202
5
2020